USAID; Children & AIDS; PEPFAR; Health Policy Plus
(2019)
C2
Policy and practice for maturity-aligned engagement of children in decisions about HIV-related medical and social services and management of confidential information
Kipling Beardsley, Health Policy Plus
Accessed: 26.10.2019
As an inter-faith network of religious leaders living with or affected by HIV, INERELA+ seeks to empower religious leaders through education, knowledge and skills to live positively, becoming symbols of hope and agents of change who will help eliminate stigma and discrimination within their congrega...tions and communities.
Accessed: 12.11.2019more
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ...Report package.
Available in different languages: http://www.emcdda.europa.eu/publications/edr/trends-developments/2019_en
more
This document aims to provide guidance to EU/EEA public health authorities, public health professionals and healthcare practitioners for the management of persons having had contact with cases of Ebola virus disease (EVD) after visiting or working in an area that is affected by EVD; also covered is ...occupational exposure to the diseasemore
The ICOPE Implementation Framework provides a score card to help assess the overall capacity of health and social care services and systems to deliver integrated care in community settings and support the development of ICOPE implementation action plans. There are 19 actions needed to implement ICOP...E on the services level (meso) and systems level (macro). The scoring process provides an evidence-based means of highlighting areas for improvement as well as establishing concrete measures of future improvementsmore
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.more
N. Rakhmanina; J. Kose; K. Wallner; et al.Elizabeth Glaser Pediatric New Horizons (Advancing Pediatric HIV Care) ; Johnson & Johnson; AIDS Foundation (Until no child has AIDS); Children & Aids
(2019)
C2